Alvin Wong, Pharm.D.
Senior Vice President, Clinical Science and Pharmacology
Dr. Wong joined Puma Biotechnology in March 2013 and in August 2017 he was appointed
Senior Vice President, Clinical Science and Pharmacology. In April 2021, he assumed
responsibility for Translational Biology and Biometrics, including Biostatistics, Programming and
Data Management, in addition to Clinical Science/Pharmacology. Dr. Wong served as Clinical
Lead of the successful FDA submissions of neratinib for the extended adjuvant treatment of
patients with early stage HER2-positive breast cancer and subsequent submission of neratinib
for patients with HER2-positive metastatic breast cancer. From 2007 to 2013, Dr. Wong was
Senior Director of Clinical development at Proteolix, Inc. (acquired by Onyx) where he managed
studies in multiple myeloma and supported the approval of Kyprolis®. Previously, he held
positions in Clinical Pharmacology and Pharmacovigilance at Novacea, where he was the project
leader of AQ4N and clinical pharmacology lead for oral vinorelbine and DN101, and in drug
safety at Genentech, where he contributed to the successful submissions of Herceptin® for
HER2-positive breast cancer, Rituxan® for patients with non-Hodgkin’s Lymphoma and Avastin®
for patients with advanced colorectal cancer.
Dr. Wong earned his Doctor of Pharmacy degree from the University of California at San
Francisco (UCSF). He was also a Clinical Professor at the UCSF School of Pharmacy from 1976 to
Puma Biotechnology, Inc.
10880 Wilshire Blvd., Suite 2150
Los Angeles, CA 90024